In breast cancer survivors, vaginal estrogen beat a moisturizer for painful dryness

Genitourinary syndrome of menopause — vaginal dryness, pain, and related symptoms caused by low estrogen — is a common and often under-treated problem for breast cancer survivors on aromatase inhibitor therapy, since these drugs work specifically by suppressing estrogen, the same hormone that's typically used to treat the syndrome itself. That therapeutic tension has left many patients defaulting to non-hormonal options out of caution. A randomized trial published this month in Breast Cancer Research and Treatment, called VEMORA, tests vaginal estrogen against a non-hormonal moisturizer directly in this specific population [s1].

The design

This randomized, controlled, open-label trial enrolled estrogen-receptor-positive breast cancer survivors receiving adjuvant aromatase inhibitor therapy who had symptomatic genitourinary syndrome of menopause [s1]. Participants were randomized to 24 weeks of either a non-hormonal vaginal moisturizer (Replens) or vaginal estrogen therapy, delivered as either vaginal tablets (Vagifem) or a vaginal ring (Estring) [s1]. The primary endpoint was change in vaginal dryness; secondary endpoints included pain during intercourse (dyspareunia), broader sexual functioning, vaginal pH, and serum estradiol levels — a safety measure tracking whether the vaginal estrogen was being absorbed into the bloodstream at levels that could counteract the aromatase inhibitor's systemic estrogen suppression [s1].

What it found

Twenty-three patients were enrolled: 11 in the vaginal estrogen group, 12 in the non-hormonal group [s1]. Both vaginal dryness and dyspareunia scores improved significantly more with vaginal estrogen than with the non-hormonal moisturizer (p = 0.049 and p = 0.048, respectively) [s1]. Vaginal pH — a marker of vaginal tissue health that shifts with estrogen exposure — decreased significantly more with vaginal estrogen (p = 0.0286) [s1]. Other domains of sexual function — libido, ability to achieve orgasm, sexual satisfaction, and relationship with partner — showed no significant difference between the two groups [s1].

On safety, serum estradiol levels remained low through the first 12 weeks of vaginal estrogen therapy [s1]. Two participants showed estradiol elevations above the study's threshold at 24 weeks (21.8 pg/mL and 16 pg/mL); both of these participants had reported non-adherence to their aromatase inhibitor therapy preceding that measurement, meaning the elevated estradiol likely reflected their reduced aromatase inhibitor use rather than systemic absorption from the vaginal estrogen itself [s1].

Why the reassuring safety signal is conditional, not absolute

The detail that both estradiol elevations traced back to reported aromatase inhibitor non-adherence, rather than to vaginal estrogen absorption alone, is the single most important nuance in this trial's safety data — it suggests vaginal estrogen, when the aromatase inhibitor is taken as prescribed, kept serum estradiol low through at least the first 12 weeks. But it also means the safety reassurance here is conditional on continued aromatase inhibitor adherence, not an unconditional guarantee that vaginal estrogen never meaningfully raises circulating estrogen in this population — a distinction the trial's own authors flag directly by noting this "minimal systemic estrogen exposure in most patients," not all patients [s1].

Why the small sample size matters more here than in many drug trials

This is a genuinely small trial — 23 total participants across two arms — for a question with real clinical stakes: whether vaginal estrogen is safe enough to recommend for breast cancer survivors on estrogen-suppressing therapy is a decision clinicians and patients have historically approached cautiously, given the theoretical risk that any systemic estrogen absorption could counteract the cancer treatment's purpose. A trial this size can detect a symptom-improvement difference (which it did, for dryness and dyspareunia) but is not well powered to rule out rare or modest safety signals with the statistical confidence a larger trial would provide.

What this doesn't establish

The trial's own authors are explicit that "larger studies with longer follow-up are needed to define long-term safety and efficacy" [s1] — a clear acknowledgment that 23 patients and 24 weeks, while providing the first prospective randomized evidence specifically in this population, doesn't settle the long-term cancer-recurrence safety question that matters most for this specific patient group. This trial was open-label, meaning both patients and researchers knew which treatment was assigned, which could influence self-reported symptom outcomes like dryness and dyspareunia scores.

What to watch

Larger, longer-duration trials confirming both the symptom benefit and, critically, the long-term cancer-recurrence safety profile of vaginal estrogen in aromatase-inhibitor-treated breast cancer survivors. This article describes hormone therapy use in a specific cancer-treatment context; it is not medical advice, and treatment decisions should be made with an oncology team.

Sources

1. VEMORA: Vaginal Estrogen versus non-hormonal MOisturizer in women Receiving Aromatase inhibitors: a randomized, controlled trial — Breast Cancer Research and Treatment, 30 July 2026